Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 9:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoplasm Metastases Clear all
Terminated Phase 2 Interventional

Matched Unrelated Donor Transplant for Metastatic Renal Cell Carcinoma

NCT00318110
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
NST using MUD for metastatic renal cell carcinoma
Procedure
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
5
States / cities
Los Angeles, California • Gainesville, Florida • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Sep 25, 2026, 9:18 AM EDT
Terminated Phase 2 Interventional Results available

Photodynamic Therapy in Treating Patients With Resectable Non-Small Cell Lung Cancer That Has Spread to the Pleura

NCT00601848
View directory record Official record
Conditions
Lung Cancer, Metastatic Cancer
Interventions
chemotherapy, porfimer sodium, immunohistochemistry staining method, laboratory biomarker analysis, spectroscopy, therapeutic conventional surgery
Drug · Other · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Sep 25, 2026, 9:18 AM EDT
Terminated Phase 3 Interventional

Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBC

NCT03326674
View directory record Official record
Conditions
Breast Cancer
Interventions
Tesetaxel and Capecitabine, Capecitabine
Drug
Lead sponsor
Odonate Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
90
States / cities
Chandler, Arizona • Goodyear, Arizona • Tucson, Arizona + 81 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Phase 1 Interventional Results available

A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

NCT05087992
View directory record Official record
Conditions
Gastrointestinal Cancer, Metastatic
Interventions
BI 905711, FOLFIRI, Bevacizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Sep 25, 2026, 9:18 AM EDT
Recruiting Not applicable Interventional

Proton Therapy in the Treatment of Liver Metastases

NCT01697371
View directory record Official record
Conditions
Liver Metastases
Interventions
Proton, Proton Radiation
Radiation
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2033
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Phase 3 Interventional Results available

Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer

NCT00519285
View directory record Official record
Conditions
Prostatic Neoplasms, Neoplasm Metastasis
Interventions
Aflibercept, Placebo (for aflibercept), Docetaxel, Prednisone or Prednisolone
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 21, 2016 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Not applicable Interventional Results available

A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs Control

NCT04796935
View directory record Official record
Conditions
Central Nervous System Infections, Pseudotumor Cerebri, Neurological Disorder, Cancer, Obstetric Procedure Pain, Orthopedic Procedure Pain, Post-Dural Puncture Headache
Interventions
Tactile Imaging (VerTouch), Control (palpation)
Device · Other
Lead sponsor
IntuiTap Medical, Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Providence, Rhode Island • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 25, 2026, 9:18 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
Imlunestrant, Exemestane, Fulvestrant, Abemaciclib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
874 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
48
States / cities
Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Phase 2 Interventional

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

NCT02125318
View directory record Official record
Conditions
Thrombocytosis, Myeloproliferative Neoplasms
Interventions
Anagrelide CR
Drug
Lead sponsor
Galena Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Burbank, California • Encinitas, California • Escondido, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 25, 2026, 9:18 AM EDT
Terminated No phase listed Observational

Photoacoustic Lymph Node Imaging

NCT03931655
View directory record Official record
Conditions
Breast Cancer
Interventions
Spectroscopic photoacoustic imaging
Diagnostic Test
Lead sponsor
Geoff Luke
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 25, 2026, 9:18 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Pembrolizumab In Central Nervous System Metastases

NCT02886585
View directory record Official record
Conditions
Brain Metastases
Interventions
Pembrolizumab, MRI, PET/CT, Stereotactic Radiosurgery
Drug · Radiation · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 25, 2026, 9:18 AM EDT
Terminated Phase 1 Interventional Results available

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

NCT02550743
View directory record Official record
Conditions
Rectal Cancer
Interventions
BYL719, Capecitabine, Radiation
Drug · Radiation
Lead sponsor
howard safran
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Phase 1Phase 2 Interventional

Utility of Endobronchial Ultrasound Guided Needle Biopsy in Early Stage Non- Small Cell Lung Cancer (NSCLC)

NCT00832715
View directory record Official record
Conditions
Lung Cancer
Interventions
EBUS-TBNA
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Sep 25, 2026, 9:18 AM EDT
Recruiting No phase listed Observational

Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining

NCT00242723
View directory record Official record
Conditions
Thoracic Cancers, Malignant Pleural Mesotheliomas NOS, Lung Cancer NOS, Esophageal Cancers NOS, Cancers of Non Thoracic Origin With Metastases to the Lungs or Pleura, Thoracic Malignancies
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 120 Years
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Phase 1Phase 2 Interventional

Feasibility of Treatment of Cancer Involving the Liver With High Dose Radiation

NCT00178243
View directory record Official record
Conditions
Liver Neoplasms, Neoplasm Metastasis
Interventions
3D Conformal Radiation Therapy and Radiosurgery
Procedure
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2006 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Phase 1 Interventional

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

NCT00037817
View directory record Official record
Conditions
Advanced Esophageal Cancers, Primary Small Cell Lung Cancers, Non-Small-Cell Lung Carcinoma, Pleural Mesotheliomas, Cancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
Interventions
Decitabine, Depsipeptide, Celecoxib
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Single Session Stereotactic Body Radiotherapy

NCT00492817
View directory record Official record
Conditions
Spinal Neoplasms
Interventions
Stereotactic Body Radiotherapy
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 25, 2026, 9:18 AM EDT
Terminated Not applicable Interventional Results available

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

NCT00608517
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate, methylprednisolone, total-body irradiation
Biological · Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Up to 50 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
4
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 25, 2026, 9:18 AM EDT
Terminated Phase 1 Interventional Results available

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

NCT03685591
View directory record Official record
Conditions
Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma, Mesothelioma, Pancreatic Neoplasms, Colorectal Neoplasms, Carcinoma, Renal Cell, Liver Neoplasms
Interventions
PF-06952229, Enzalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
15
States / cities
Scottsdale, Arizona • Santa Monica, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 25, 2026, 9:18 AM EDT
Recruiting No phase listed Observational

Collection and Storage of Tissue and Blood Samples From Patients With Cancer

NCT02474160
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
Interventions
Cytology Specimen Collection Procedure
Other
Lead sponsor
National Cancer Institute LAO
Other
Eligibility
2 Months and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
140
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Arroyo Grande, California + 95 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Sep 25, 2026, 9:18 AM EDT
Active, not recruiting Not applicable Interventional

Palliative Spatially Fractionated (GRID) Radiotherapy Using Intensity Modulated Proton Therapy

NCT05831579
View directory record Official record
Conditions
Unresectable Solid Tumor, Metastatic Cancer
Interventions
Proton GRID Radiotherapy
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Phase 1 Interventional Results available

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

NCT02159989
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Fibrolamellar Carcinoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Neuroendocrine Tumor, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Solid Neoplasm
Interventions
Sapanisertib, Ziv-Aflibercept
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 25, 2026, 9:18 AM EDT
Completed Phase 1 Interventional Results available

A Dose-Escalation Study in Participants With Advanced Cancer

NCT01524224
View directory record Official record
Conditions
Advanced Cancer
Interventions
LY2495655
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
7
States / cities
Scottsdale, Arizona • New York, New York • Nashville, Tennessee + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Sep 25, 2026, 9:18 AM EDT
Terminated No phase listed Observational

GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study

NCT00595296
View directory record Official record
Conditions
Breast Cancer
Interventions
GeneSearch™ Breast Lymph Node (BLN) Assay
Device
Lead sponsor
Janssen Diagnostics, LLC
Industry
Eligibility
18 Years and older
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Sep 25, 2026, 9:18 AM EDT